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Abstract
Background Sublingually administered asenapine was
approved in March 2015 by the United States Food and
Drug Administration for patients aged 10–17 years with an
acute manic or mixed episode associated with bipolar I
disorder (BP-1). This is the first long-term safety and tol-
erability study of asenapine in this population.
Methods Following the 3-week randomized, double-blind,
placebo-controlled trial of patients aged 10–17 years with
an acute manic or mixed episode associated with BP-1,
patients could enroll in this flexible-dose (2.5–10 mg twice
daily) open-label extension (OLE) study for an additional
50 weeks, conducted from August 2011 to September 2014
in the United States and Russia. Treatment-emergent
adverse events (TEAEs) were assessed and predefined
TEAEs of interest reported in addition to metabolic and
anthropometric parameters. The Young Mania Rating
Scale (YMRS) and Clinical Global Impressions scale in
bipolar illness (CGI-BP) were used to assess effectiveness.
Results A total of 321 patients (lead-in study treatment:
placebo, n = 80; asenapine, n = 241) were included; 267
(83.2 %) reported one or more TEAE and 181 (56.4 %)
discontinued early, 48 (15.0 %) due to TEAEs. Of the
predefined TEAEs of interest, combined somnolence/se-
dation/hypersomnia occurred most frequently (42.4 %)
followed by oral hypoesthesia/dysgeusia (7.5 %). In total,
109 (34.8 %) patients experienced clinically significant
weight gain (C7 % increase). No clinically meaningful
changes were noted for laboratory parameters measured.
Eighteen patients met the criteria for new-onset metabolic
syndrome (MBS) post-baseline during the extension study,
whereas 10 patients who met MBS criteria at baseline did
not meet MBS criteria at endpoint. A total of 12 patients
met MBS at baseline and endpoint. Mean change in YMRS
total score from OLE baseline was -9.2 points at week 50,
and change in CGI-BP severity overall score was similar
among all treatment groups (those who initially received
asenapine and those who initially received placebo). After
26 weeks of treatment in the OLE, 79.2 % of patients were
classified as YMRS 50 % responders relative to acute trial
baseline.
Conclusions Asenapine was generally well tolerated in
pediatric patients with BP-1 during B50 weeks of open-
label treatment; among predefined TEAEs of interest, the
combination of somnolence/sedation/hypersomnia was the
most common.
Trial registration ClinicalTrials.gov: NCT01349907.
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article (doi:10.1007/s40272-016-0184-2) contains supplementary
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Key Points
Long-term flexible dose administration of sublingual
asenapine was generally well tolerated in pediatric
patients with a manic or mixed episode associated
with bipolar I disorder.
Fifteen percent of patients discontinued due to
treatment-emergent adverse events; clinically
significant weight gain was experienced by 34.8 %
of patients.
Among the predefined treatment-emergent adverse
events of interest, the combination of somnolence,
sedation, and hypersomnia was most frequent
(42.4 % of patients).
1 Introduction
Many patients with bipolar I disorder (BP-1) experience
onset of mania prior to adulthood, and evidence suggests
that BP-1 is relatively common in pediatric-aged patients; a
cross-sectional survey of more than 10,000 American
adolescents aged 13–18 years identified in household and
school settings estimated that the lifetime prevalence of
BP-1 was 1.7 % [1]. These data are similar to results of an
earlier meta-analysis of more than 16,000 young people
aged 7–21 years, which estimated the lifetime prevalence
of BP-1 to be 1.8 %, with no difference observed between
US and non-US populations [2]. Freeman and colleagues
[3] reported that the quality of life associated with pediatric
bipolar disorder is more burdensome than a variety of
physical conditions and appears to have a greater impact
than other pediatric psychiatric conditions.
Individuals who experience BP-1 earlier in life are
expected to develop a more chronic, severe, and recurrent
course of the disease when compared with individuals who
developed the disorder in adulthood [4–7]. Bipolar disorder
is a major cause of disability in young people [8].
Asenapine is a sublingually administered second-gen-
eration atypical antipsychotic. In the United States, ase-
napine was approved in adults for use as monotherapy
(August 2009) or adjunctive therapy with lithium or val-
proate (September 2010) for manic or mixed episodes
associated with BP-1. In March 2015, asenapine was
approved by the US Food and Drug Administration (FDA)
for use as monotherapy in pediatric patients aged
10–17 years with an acute manic or mixed episode asso-
ciated with BP-1 [9]. Asenapine is not approved for the
treatment of pediatric patients with BP-1 outside of the US,
but is approved or registered in 65 countries as
monotherapy for the treatment of adults with BP-1.
Because BP-1 is a chronic illness and a serious condi-
tion, long-term treatment is usually necessary. There are
presently no long-term data available on the safety and
tolerability of asenapine in pediatric patients with BP-1 of
which we are aware. In general, there are limited empirical
data that describe the long-term safety of any second-
generation antipsychotics in pediatric patients. Completed
studies have shown evidence that sedation, hyperpro-
lactinemia, and metabolic abnormalities may develop
during pharmacotherapy with this class of medications
[10]. Therefore, in this study, we sought to characterize the
safety of asenapine over 50 weeks in an open-label
extension (OLE) trial.
2 Methods
Details of the antecedent 3-week, randomized, double-
blind, placebo-controlled efficacy and safety trial of ase-
napine in pediatric patients with an acute manic or mixed
episode associated with BP-1 (NCT01244815) have been
previously published [11]. In brief, patients were random-
ized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg twice
daily (bid) for 3 weeks (see electronic supplementary
material [ESM], Online Resource 1). After completing the
acute trial, patients could enroll in this 50-week OLE trial.
The first day of the OLE trial overlapped with day 21/end-
of-treatment period for the acute mania trial. The OLE was
a flexible-dose, multicenter trial to evaluate the long-term
safety and tolerability of asenapine monotherapy in pedi-
atric patients aged 10–17 years with a manic or mixed
episode associated with BP-1 (NCT01349907); the trial
was conducted from August 16, 2011 to September 5,
2014, in the United States and Russia. Diagnosis of BP-1
was made according to the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition, text revision
(DSM-IV-TR) with current manic (296.4x) or mixed
(296.6x) episode with or without psychotic features
required and confirmed by a structured clinical interview
which consisted of a medical and psychiatric history,
DSM-IV-TR checklist, and the Kiddie-Schedule for
Affective Disorders and Schizophrenia—Present and
Lifetime Version at screening before enrollment in the
acute trial.
Independent Ethics Committees associated with each
study site reviewed and approved the protocol and appli-
cable amendments. The study was conducted in accordance
with Good Clinical Practice standards and applicable
country and/or local statutes and regulations regarding
ethical committee review, informed consent, and the pro-
tection of human patients participating in biomedical
research. Written informed consent was provided by the
patient’s parent, legal representative, or caretaker and
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written patient assent was also obtained before any trial
procedures or assessments were performed. If at any time
during the patient’s participation they turned 18 years of
age, they were asked to provide written informed consent.
This was an open-label trial and therefore did not require
the use of blinding procedures although the blind was
maintained with respect to the acute phase trial until that
database was unlocked. An external Data Monitoring
Committee met regularly to evaluate safety data in an
unblinded fashion during the course of the trial. The OLE
was initially designed as a 26-week study and amended to
50 weeks to meet European Medicines Agency require-
ments. The protocol was also amended to include subjects
of younger age (10 and 11 years) and older age (18 years
of age). Although patients aged 18 years were permitted to
enroll in the OLE, predefined analyses were limited to ages
B17 at OLE entry; the one patient who was aged 18 at
entry was therefore excluded from analyses.
2.1 Inclusion Criteria
Patients aged 10–18 years who both completed the acute
trial and who, in the investigator’s opinion, could poten-
tially benefit from long-term asenapine treatment were
eligible for enrollment. Key inclusion criteria from the
acute trial included a primary diagnosis of BP-1 according
to the DSM-IV-TR with a current manic (296.4x) or mixed
(296.6x) episode with or without psychotic features (con-
firmed by a structured clinical interview that consisted of a
medical and psychiatric history, DSM-IV-TR checklist,
and the Kiddie-Schedule for Schizophrenia and Affective
Disorders—Present and Lifetime Version at screening), a
Young Mania Rating Scale (YMRS) score C20, and an
overall severity of bipolar mania and depression C4 on the
Clinical Global Impressions scale in bipolar illness (CGI-
BP). For enrollment in the OLE, patients were required to
demonstrate an acceptable level of adherence to antecedent
trial medication, study visits, and other protocol require-
ments in the acute trial according to the investigators’
opinion, and to have a caregiver living with them able to
provide continued support for adherence to the study
protocol.
2.2 Exclusion Criteria
Patients with a pervasive development disorder,
schizophrenia, schizoaffective disorder, post-traumatic
stress disorder, obsessive–compulsive disorder, or psy-
chosis due to a medical condition or prohibited concomi-
tant medication were excluded from the acute trial. Patients
with a positive urine pregnancy test at OLE baseline or
with the intention to become pregnant during the trial were
excluded. Additional criteria that warranted exclusion from
the OLE included being at imminent risk of self-harm or
harm to others, in the investigator’s opinion, based on
clinical interview and responses provided on the Columbia
Suicide Severity Rating Scale (C-SSRS), involuntary
inpatient commitment, poor adherence to the acute trial
protocol, and known serological evidence of human
immunodeficiency virus antibody. In addition, patients
with an uncontrolled, unstable, clinically significant med-
ical condition were excluded. Prohibited concomitant
medications included all psychotropic drugs with the
exception of stimulants (for attention-deficit hyperactivity
disorder [ADHD]) and short-acting benzodiazepines (for
transient agitation, irritability, restlessness, insomnia, and
hostility). Anticholinergics were also allowed as a rescue
medication for extrapyramidal symptoms (EPS).
2.3 Dosing
All patients, whether treated with asenapine or placebo in
the acute trial, were administered open-label asenapine
formulated as a fast-dissolving, black-cherry-flavored
sublingual tablet at 2.5 mg bid on day 1. On the evening of
day 4, the asenapine dose was increased to 5 mg bid. At the
day 7 visit, the asenapine dose was increased to 10 mg bid,
if tolerated, beginning with the evening dose. The dose was
increased sooner, at the discretion of the investigator, if
clinically warranted. From day 7 onward, asenapine dosing
was flexible based on tolerability and/or symptomatology.
Study visits also occurred on days 14, 28, 42, 70, 98, 126,
154, 182, 210, 238, 266, 294, 322, and 350 (see ESM,
Online Resource 1).
2.4 Safety Outcomes
There were no prespecified key safety endpoints; explora-
tory safety events and tolerability parameters were assessed
throughout the trial (i.e., vital signs were recorded at every
study visit; laboratory tests were administered at visits 14,
18, 20, 25, and 28 [i.e., days 28, 126, 182, 266, 350]; and
anthropometric parameters were assessed at visits 13, 14,
16, 18, and 20 through 28 [i.e., days 14, 28, 70, 126, and
182–350]). Adverse events were recorded based on spon-
taneous report or investigator observation; reported adverse
events were monitored with the relevant clinical assess-
ments and/or laboratory tests. An adverse event was con-
sidered treatment emergent (TEAE) if it was newly
reported after open-label baseline or reported to have
worsened in severity since open-label baseline. Predefined
TEAEs of interest in the study were akathisia, dizziness,
insomnia, somnolence/hypersomnia/sedation combined,
oral hypoesthesia/dysgeusia, EPS, and incidence of clini-
cally significant weight increase (defined as C7 % increase
from baseline to endpoint according to the US FDA
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guidance and product prescribing information) [9]. The
Extrapyramidal Symptom Rating Scale (ESRS) was used to
measure EPS [12]. The ESRS consisted of scores on EPS-
related items, leading to nine derived parameter scores.
Ratings were made through a combination of clinical
interview and motor examination. Further, events related to
suicidality (e.g., suicidal ideation, suicidal behavior, and/or
non-suicidal self-injurious behavior) were summarized
based on responses to the C-SSRS at each visit [13].
Analysis of safety data also focused on mean changes
from the OLE baseline in the following laboratory
parameters: fasting glucose, fasting triglycerides, fasting
cholesterol, prolactin, fasting insulin, and glycosylated
hemoglobin (HbA1c). Laboratory values were obtained at
baseline and on days 28, 126, 182, 266, and 350. TEAEs
potentially related to new-onset diabetes mellitus were
analyzed by grouping for summary purposes hyper-
glycemia, new-onset diabetes mellitus, increased weight,
increased appetite, increased blood glucose, central obe-
sity, hyperlipidemia, and loss of consciousness as defined
in the Medical Dictionary for Regulatory Activities
(MedDRA) by the standardized MedDRA query (SMQ)
‘hyperglycemia/new onset diabetes (broad)’. The criteria
for metabolic syndrome (MBS) was defined by the Inter-
national Diabetes Federation, which includes abdominal
girth (measured throughout the trial, in centimeters) plus
two other laboratory values (triglycerides, high-density
lipoprotein cholesterol, blood pressure, or glucose), all of
which had to be met at the same visit for a MBS diagnosis
[14, 15]. MBS was further categorized based on the study
period (i.e., baseline and/or treatment periods).
2.5 Effectiveness Outcomes
The following select exploratory parameters were assessed
during the study: change in YMRS total score from base-
line(s) (pre-treatment and open-label); time to failure to
maintain effect from open-label baseline to any time point
(i.e., a\50 % reduction from baseline in YMRS total score
for patients who achieved a 50 % YMRS response during
the acute trial and lost the effect during the OLE); total
YMRS 50 % responders and remitters (i.e., those who
achieved C50 % improvement in YMRS total score from
each respective trial baseline to endpoint were considered
responders, and remitters required a YMRS total score
B12); and change in CGI-BP severity scale overall score
from OLE baseline. The YMRS is an 11-item clinician-
rated scale to assess the severity and symptoms of manic
episodes and can range from 0 (all symptoms absent) to 60
(all symptoms extreme) [16–18]. A decrease in YMRS
total score is indicative of improved symptoms. The YMRS
was administered at baseline and on days 28, 70, 126, 182,
266, and 350. The CGI-BP severity scale is a single-item
clinician-rated scale with a possible score of 1–7, where
higher scores indicate greater severity [19]. The CGI-BP
severity scale was administered on days 7, 14, 28, 42, 70,
98, 126, 154, 182, 210, 238, 266, 294, 322, and 350.
2.6 Sample Size
No formal sample size calculation was performed because
this was a single-arm OLE trial and the primary objective
was evaluation of safety and tolerability. The number of
patients enrolled in this trial was dependent on the number
of patients completing the double-blind acute trial and was
expected to be C280 patients (approximately 70 % of
patients enrolled in the acute trial).
2.7 Statistical Analysis
Analysis of safety data used the all-patients-as-treated
(APaT) population, defined as all patients B17 years old
who received one or more dose of open-label trial medi-
cation. For analysis of safety parameters from the OLE
baseline (or last day of the antecedent acute trial treat-
ment), categorical variables were summarized as numbers
and percentages. For continuous variables (such as changes
from baseline), mean, median, minimum, and standard
deviation (SD) were provided as summary measures.
Additionally, within-group point estimates were provided.
For the select TEAEs of interest and TEAEs that occurred
in four or more patients overall, 2-sided 95 % confidence
intervals (CIs) were provided for the within-group per-
centage of patients with events using the 2-tailed exact
binomial method proposed by Clopper–Pearson [20]. For
continuous measures, 2-sided 95 % CIs were provided for
within-group differences using an analysis of covariance
model with terms for pooled site, identified group, and
baseline value (if applicable). Predefined limits of change
were summarized using frequency tables for each visit and
endpoint (if applicable) and shifts from baseline to post-
baseline and endpoint (if applicable) by identified group.
Changes in body weight and body mass index (BMI)
were also adjusted for growth (age and sex) and presented
as mean Z-scores [21]. The Z-scores are assumed to follow
a standard normal distribution and indicate how many SDs
an observed value is away from the expected growth (i.e.,
weight, height, BMI), based on an individual’s age and sex.
Each Z-score corresponds to a percentile in the standard-
ized growth curve. A Z-score of 0 corresponds to a 50th
percentile (the median), whereas a negative Z-score cor-
responds to a percentile below the median and a positive
Z-score corresponds to a percentile above the median. The
distance of a Z-score from 0 represents the distance of a
percentile from the median. For the countries included in
this trial (USA and Russia), age- and sex-adjusted growth
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was compared with expected growth seen in the general US
population using the most recent growth charts at the time
of database lock as provided by the National Center for
Health Statistics (NCHS) [21]. A SAS program is available
from the NCHS website that provides Z-scores and per-
centiles for weight, height, and BMI based on the US
Centers for Disease Control and Prevention growth charts
[21]. The Centers for Disease Control and Prevention ref-
erence database based on the US population may not be
representative of sites outside the United States.
Efficacy analysis used the full analysis set population,
defined as patients B17 years old who received one or
more dose of open-label trial medication and had one or
more open-label postbaseline in-treatment YMRS total
score. Efficacy results (YMRS total score, CGI-BP severity
overall score, and total YMRS 50 % responders) were
evaluated using last observation carried forward (LOCF)
and observed cases (OC) approaches. For LOCF analysis,
the value of a particular assessment was the last available
non-missing value prior to the particular assessment when
the value was missing. In the OC approach, the assessment
closest to the scheduled assessment day within the allowed
window was used. If there were two assessments within the
same absolute distance of the scheduled assessment, the
one with the later date was chosen as OC. Kaplan–Meier
analysis was used to estimate the time to failure to maintain
response and was limited to those patients at endpoint in
the acute trial who were considered total YMRS 50 %
responders. Days to failure to maintain response was
defined as the number of days from first achieving
responder status to the first subsequent time that the patient
had less than a 50 % reduction from open-label baseline in
YMRS total score. A patient was considered a YMRS
responder at a given visit if they experienced a 50 % or
more decrease from acute trial baseline in YMRS total
score at that visit.
3 Results
3.1 Patients
A total of 350 patients completed the acute trial and 322
(92.0 %) were treated with open-label asenapine; 321 were
included in the analyses (Fig. 1). As predefined analyses
were limited to patients aged B17 years at OLE entry, the
one patient aged 18 years at entry was excluded from these
analyses. Of the 321 included patients, 80 had been treated
with placebo and 241 treated with asenapine in the ante-
cedent acute phase trial. The mean age was
13.8 ± 2.0 years for the overall OLE population (Table 1).
Other baseline demographic characteristics were similar
between groups. The majority of patients in the total
treatment group were White (69.8 %) and had a mean BMI
of 24.6 ± 6.3. The most common comorbid Axis I disorder
among the overall patient population was ADHD, which
was diagnosed in 182 (56.7 %) patients, of whom 88
(48.4 %) were prescribed stimulants and 94 (51.6 %) were
not. For the total treatment group, overall asenapine
exposure ranged from 2 to 380 days, with a median dura-
tion of 182 days of treatment. Overall, 107 (33 %) patients
were exposed to asenapine 2.5 mg, 5 mg, or 10 mg bid for
at least 230 days. In the overall study population, 31
(9.7 %) patients received a modal dose of asenapine
2.5 mg bid, 105 (32.7 %) patients received 5 mg bid, and
170 (53.0 %) patients received 10 mg bid. There were 15
(4.7 %) patients that received treatment for \8 days for
which no modal dose was determined.
Concomitant medication use was reported by 69.8 % of
patients in the APaT population. The most commonly used
medications were propionic acid derivatives (18.4 %; e.g.,
ibuprofen), sympathomimetics (16.5 %; e.g., methylphe-
nidate), benzodiazepine derivatives (12.5 %; e.g., lor-
azepam), anilides (12.1 %; e.g., paracetamol), and mixed
amphetamine salts (10.3 %).
3.2 Safety
No deaths occurred during the trial (Table 2). Overall, 267
(83.2 %) patients reported TEAEs in the total treatment
group. Serious adverse events (SAEs) were reported in a
total of 22 (6.9 %) patients. Most SAEs belonged to the
psychiatric disorders class (i.e., suicidal ideation, aggres-
sion, bipolar disorder, depression, agitation). Overall, 13
(4.0 %) patients in the total treatment group discontinued
treatment as a result of SAEs. The SAEs that led to dis-
continuation among these 13 patients included ADHD,
aggression (n = 2), agitation, anxiety, bipolar disorder,
depression, dystonia, intentional overdose, suicidal
behavior, and suicidal ideation (n = 3). Additionally, 181
(56.4 %) patients discontinued from the total treatment
group; the most common reasons were attributed to AEs
(48, 15.0 %), nonadherence to the study protocol (46,
14.3 %), and consent withdrawal (38, 11.8 %). The most
common individual TEAEs leading to discontinuation in
the overall population were somnolence (1.9 %), sedation
(1.2 %), and fatigue (1.2 %).
Per the C-SSRS, 295 (91.9 %) of the 321 patients
reported no positive responses (i.e., affirmative responses
to questions on the C-SSRS) and one patient did not have
C-SSRS data. Of the 25 (7.8 %) patients with positive
responses on the C-SSRS, 23 (7.2 %) had some degree of
suicidal ideation and/or behavior per the C-SSRS. The
majority of the suicidal ideation was reported as passive or
non-specific, or ideation without a plan or intent. A total of
8 of the 25 (32.0 %) patients with positive C-SSRS
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responses reported self-injurious behavior with no suicidal
intent on the C-SSRS. Further, 19 (5.9 %) patients in the
total treatment group had AEs or TEAEs of suicidality,
including 10 patients for which these were considered
serious. Of these 10 patients with serious TEAEs related to
suicidality, one patient had a suicide attempt (melatonin
overdose). Further, three patients discontinued due to sui-
cidal ideation and two for suicidal behavior. During the
trial, five accidental overdoses associated with asenapine
were recorded as TEAEs; overdose was defined as any dose
greater than the daily dose specified in the protocol.
Of the predefined TEAEs of interest (Table 2), the
combination of somnolence, sedation, and hypersomnia
occurred most frequently (136 or 42.4 % of the total treat-
ment group; 60.0 % of placebo/asenapine patients and
36.5 % of asenapine/asenapine patients) followed by the
combination of oral hypoesthesia and dysgeusia (7.5 %
overall), EPS (6.2 % overall), and dizziness (4.7 % over-
all). With the exceptions of insomnia and C7 % weight gain
from baseline to endpoint, which were reported with similar
frequency between the OLE groups, as expected the pla-
cebo/asenapine group had a greater frequency of all other
TEAEs of interest compared with the asenapine/asenapine
group. Most TEAEs were reported to be mild or moderate in
severity. The most commonly reported TEAEs that were
reported in C5 % of the total treatment group were som-
nolence, increased weight, sedation, headache, nausea,
vomiting, fatigue, increased appetite, upper abdominal pain,
and oral hypoesthesia (see ESM, Online Resource 2).
Mean increases in all growth parameters (weight, height,
BMI, and abdominal girth) were observed; however, rela-
tive increases in weight exceeded those in height (children
and adolescents are expected to gain weight and grow in
height as part of normal development) as suggested by the
observed increases in BMI. In the total treatment group,
109 (34.8 %) patients experienced clinically significant
(C7 %) weight gain (Table 2). TEAEs of weight gain were
reported for 58 (18.1 %) patients. After correcting for age
and sex, the mean weight and BMI scores at baseline and
endpoint demonstrated an increase (Table 3). Weight cat-
egory shifts were observed from the OLE baseline; more
patients had upward shifts than downward shifts (see ESM,
Online Resource 3). The mean change from baseline in
weight percentile increased over time during the acute trial,
and continued to increase initially during the OLE and
appeared to stabilize temporally with continued treatment
(see ESM, Online Resource 4). Results indicate that posi-
tive mean changes in BMI percentiles did not increase after
week 18 (mean BMI percentile change of 3.9 at day 266)
(see ESM, Online Resource 5). This is consistent with the
corresponding weight percentile, where the maximum
mean change in weight percentile occurred at week 18 (4.9
at day 266).
No clinically meaningful changes were noted in the
laboratory parameters measured (Table 4). There were no
patients with reported TEAEs with the specific preferred
terms of hyperglycemia or new-onset diabetes. However,
using the broad MedDRA definition, additional terms were
included in the definition of new-onset diabetes mellitus
(increased weight, increased appetite, increased blood
glucose, central obesity, hyperlipidemia, and loss of con-
sciousness). In the total treatment group, 73 (22.7 %)
patients reported TEAEs within the broad scope of those
pertaining to new-onset diabetes mellitus. Additionally,
Completed acute trial (N=350)






Adverse events b 11 (13.8)
Reasons:
Treatment failure 4 (5.0)
Lost to follow-up 5 (6.3)








Adverse events b 37 (15.4)
Reasons:
Treatment failure 13 (5.4)
Lost to follow-up 25 (10.4)








Adverse events b 48 (15.0)
Reasons:
Treatment failure 17 (5.3)
Lost to follow-up 30 (9.3)





Fig. 1 Patient disposition.
aDiscontinued and Completed
consists of a mixture of patients
who discontinued/completed the
26-week and 50-week versions
of the protocol; bthe most
common adverse events leading
to treatment discontinuation
were due to disease under study
and occurred in 3 patients from
the placebo/asenapine group
and 10 patients from the
asenapine/asenapine group (13
patients in total)
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there were two TEAEs of increased blood glucose and six
cases of increased blood insulin; all of which were of mild
or moderate intensity. In total, 18 patients met new-onset
MBS criteria post-baseline during the extension study,
whereas 10 patients who met MBS criteria at baseline did
not meet MBS criteria at endpoint. A total of 12 patients
met MBS at baseline and endpoint.
3.3 Efficacy
Change in YMRS total score from the acute trial baseline
in this uncontrolled trial indicates that the improvement in
mania, as measured by the mean change in YMRS total
score from baseline, was maintained over the course of the
extension trial for patients who were treated with asenapine
in the acute trial (Fig. 2a). Mean change in YMRS total
score from OLE baseline at week 26 was -6.9 points in the
total treatment group and was of a greater magnitude in the
placebo/asenapine group (-13.0 points) versus the ase-
napine/asenapine group (-4.9 points). Week 50 results for
total YMRS score were similar with a mean change of -
9.2 points observed in the total treatment group, -15.2 in
the placebo/asenapine group, and -6.5 in the asenapine/
asenapine group. Similar trends over time were observed
with the LOCF approach.
Likewise, the change in CGI-BP severity overall score
was similar among all treatment groups, indicating effec-
tiveness was maintained over the course of the trial
(Fig. 2b). The LOCF approach yielded consistent results.
Of the 141 patients who were total YMRS 50 %
responders at the end of the acute trial and who were
included in the OLE, 46 patients (32.6 %) failed to
Table 1 Open-label extension baseline demographic and clinical characteristics of all patients aged 10–17 years with manic or mixed episodes






N = 80 N = 241 N = 321
Age, years, mean (SD) 13.7 (2.0) 13.8 (2.0) 13.8 (2.0)
Sex, n (%)
Male 33 (41.3) 128 (53.1) 161 (50.2)
Female 47 (58.8) 113 (46.9) 160 (49.8)
Race, n (%)
White 57 (71.3) 167 (69.3) 224 (69.8)
Black 15 (18.8) 58 (24.1) 73 (22.7)
Asian, American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander 0 5 (2.1) 5 (1.6)
Multiracial 8 (10.0) 11 (4.6) 19 (5.9)
Weight, kg, mean (SD) 66.8 (23.7) 63.8 (20.3) 64.5 (21.2)
BMI, kg/m2, mean (SD) 25.3 (6.5) 24.3 (6.3) 24.6 (6.3)
Abdominal girth, cm, mean (SD) 82.4 (16.1) 80.4 (15.7) 80.9 (15.8)
Region, n (%)
USA 75 (93.8) 227 (94.2) 302 (94.1)
Non-USA 5 (6.3) 14 (5.8) 19 (5.9)
Age of onset, years, at entry in the acute trial, n (%)
B12 25 (31.3) 68 (28.2) 93 (29.0)
[12 55 (68.8) 173 (71.8) 228 (71.0)
Comorbid ADHD, n (%)
Yes, concomitant stimulant use, yes 21 (26.3) 67 (27.8) 88 (27.4)
Yes, concomitant stimulant use, no 24 (30.0) 70 (29.0) 94 (29.3)
No, concomitant stimulant use, yes 1 (1.3) 0 1 (0.3)
No, concomitant stimulant use, no 34 (42.5) 104 (43.2) 138 (43.0)
YMRS total score, mean (SD)a 20.2 (8.7) 15.3 (8.7) 16.5 (9.0)
CGI-BP overall score, mean (SD)a 3.7 (0.9) 3.1 (1.0) 3.2 (1.0)
ADHD attention-deficit hyperactivity disorder, BMI body mass index, CGI-BP Clinical Global Impression scale for use in bipolar illness, SD
standard deviation, USA United States of America, YMRS Young Mania Rating Scale
a Placebo/asenapine n = 72, asenapine/asenapine n = 227, total n = 299
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maintain effect in the OLE. At day 182 (week 26), the
Kaplan–Meier estimate of the cumulative percentage of
failures to maintain effect was 31.1 % in the total treatment
group.
After 26 weeks of treatment in the OLE, a total of 118
of 149 (79.2 %) patients were total YMRS 50 % respon-
ders using the acute trial baseline; YMRS remission
(YMRS total score B12) was reached by 102 of 149
(68.5 %) patients at the end of treatment in the OLE. Of
note, 26-week data were used owing to the limited number
of patients with data values after week 26.
4 Discussion
Flexibly dosed asenapine (2.5 mg, 5 mg, and 10 mg bid)
was generally well tolerated in pediatric patients with an
acute manic or mixed episode associated with BP-1 treated










Any TEAEb 74 (92.5) 193 (80.1) 267 (83.2)
Death 0 0 0
SAE 5 (6.3) 17 (7.1) 22 (6.9)
Discontinuation caused by TEAE 11 (13.8) 37 (15.4) 48 (15.0)
C1 predefined TEAE of interest during the studyb
Somnolence, sedation, and hypersomnia combined 48 (60.0) 88 (36.5) 136 (42.4)
Dizziness 9 (11.3) 6 (2.5) 15 (4.7)
Insomnia 2 (2.5) 6 (2.5) 8 (2.5)
Oral hypoesthesia and dysgeusia 15 (18.8) 9 (3.7) 24 (7.5)
EPSc 6 (7.5) 14 (5.8) 20 (6.2)
Akathisia 3 (3.8) 7 (2.9) 10 (3.1)
C7 % weight increase from baseline to endpoint, n/n1 (%) 28/75 (37.3) 81/238 (34.0) 109/313 (34.8)
EPS extrapyramidal symptom, n1 number of patients available for assessment, OLE open-label extension, SAE serious adverse event, TEAE
treatment-emergent adverse event
a TEAEs were counted from the open-label baseline; TEAEs were newly reported in the OLE or worsened in severity during the OLE compared
with the acute phase
b Every patient was counted a single time for each applicable row and column
c Includes the preferred terms akathisia, dyskinesia, dystonia, and Parkinson-like events
Table 3 Z-scoresa for weight and BMI asenapine-treated pediatric patients with bipolar I disorder







Baseline 1.11 (1.16) 0.83 (1.19) 0.90 (1.18)
Endpoint 1.21 (1.14) 0.91 (1.18) 0.98 (1.17)
Changeb 0.10 (0.32) 0.08 (0.36) 0.08 (0.35)
BMI, kg/m2
Baseline 1.15 (0.98) 0.88 (1.15) 0.94 (1.12)
Endpoint 1.25 (0.98) 0.93 (1.19) 1.00 (1.15)
Changeb 0.10 (0.31) 0.05 (0.49) 0.06 (0.45)
BMI body mass index, SD standard deviation
a Z-score indicates how many SDs a value is away from the expected value for a person of the same sex and age. A Z-score of 0 corresponds to
the 50th percentile (i.e., the median), a negative Z-score corresponds to a percentile below the median, and a positive Z-score corresponds to a
percentile above the median. Percentiles are corrected for age and sex
b Change from baseline to endpoint was calculated using the open-label baseline
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for up to 50 weeks. Somnolence (26.8 %), weight gain
(18.1 %), sedation (15.9 %), and headache (12.8 %) were
the most commonly reported individual TEAEs and som-
nolence, sedation, and fatigue were the most common
TEAEs leading to discontinuation in the OLE (1.9, 1.2, and
1.2 %, respectively). These TEAEs, combined with dizzi-
ness and oral hypoesthesia, occurred more frequently in
asenapine-naı¨ve patients and may, therefore, be TEAEs to
consider monitoring with initiation of asenapine in this
population. Additionally, SAEs that led to discontinuation
included ADHD, aggression, agitation, anxiety, dystonia,
intentional overdose, suicidal behavior, and suicidal idea-
tion. These SAEs are as expected for a long-term, open-
label study in this patient population, making it difficult to
interpret if, or how, they are related to the study medica-
tion. That said, during the acute trial the incidence of these
SAEs was higher in those randomized to receive asenapine
compared with placebo [11].
A total of 34.8 % of patients experienced clinically
significant weight increase (defined as C7 % increase in
body weight at endpoint based on the current US FDA
guidance and product label). Weight gain is common with
other atypical antipsychotics in children and adolescents
[22]. However, it should be noted that children and ado-
lescents are expected to experience a degree of weight gain
that is attributable to normal growth, especially considering
the duration of this long-term trial. In the present study, the
overall mean (SD) weight gain at endpoint was 3.5 (5.8)
kg. Weight gain based on weight percentile (adjusted for
growth, as based on age and sex) continued to increase
after treatment initiation in this extension trial, which is
consistent with alterations observed in fasting metabolic
parameters (i.e., total cholesterol, high-density lipoprotein,
low-density lipoproteins, triglycerides, glucose, and insu-
lin) in a minority of patients at study endpoint. Results of
patients meeting criteria for MBS suggest that asenapine
may be temporally associated with development of MBS in
some patients. Therefore, metabolic monitoring should be
performed in pediatric patients initiating therapy with
asenapine and, in addition, healthy lifestyle instruction
should accompany treatment.
An average improvement in the YMRS total score and
CGI-BP severity score was seen over time in this uncon-
trolled trial. In addition, patients who transitioned to ase-
napine in the OLE after receiving placebo during the acute
phase essentially achieved the same level of response as the
asenapine/asenapine group by the end of the extension
study. Of note, almost one third of patients who met the
criterion for response (50 % improvement in YMRS) at the
end of the acute trial failed to sustain this level of
improvement at all visits during the OLE. This may be a
reflection of the strict maintenance criterion since patients
were assessed as having failed to maintain response even if
the drop below the 50 % improvement threshold was
temporary and response was regained at subsequent visits.
Additionally, since fluctuation of symptoms in bipolar
disorder may be more common in pediatric patients than in
adult patients [5], patients who failed to maintain response
at every assessment may have experienced symptom fluc-
tuation that is characteristic of the pediatric course of the
disorder. However, after 26 weeks of open-label asenapine
treatment, 79 % of patients were YMRS 50 % responders
and 68 % of patients achieved YMRS remission (YMRS
total score B12), suggesting that a large proportion of
patients achieved clinically meaningful symptom
improvement.
4.1 Limitations
Although this study had a relatively large sample size, it
was an open-label study and efficacy and safety results
should be interpreted with caution. In addition, over half of
the patients in this study discontinued prematurely which
may limit generalizability of these results; however, the
completion rate (44.6 %) in this study was similar to that
seen in other long-term studies of antipsychotics in ado-
lescent populations [23–25] and may be related to the
length of the trial and the ages of the patients. Furthermore,







Fasting cholesterol, mg/dL 2.67 (22.93) -3.40 (22.31) -1.89 (22.54)
Fasting triglycerides, mg/dL 0.62 (50.97) -0.97 (58.76) -0.53 (56.81)
Fasting glucose, mg/dL 0.90 (13.33) 1.26 (13.69) 1.26 (13.51)
HbA1c (C7 %), n 0 0 0
Fasting insulin, lU/mL 4.51 (19.72) -6.35 (55.72) -3.58 (49.27)
Prolactin, ng/mL 2.31 (12.30) -0.39 (14.07) 0.27 (13.69)
HbA1c glycosylated hemoglobin, SD standard deviation
a Mean changes and shifts were calculated using the open-label extension baseline
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results may not be generalizable to the entire child and
adolescent population with BP-1 due to the inclusion and
exclusion criteria used in this study. While not a limitation
of the study per se, accurate diagnosis of BP-1 in pediatric
patients may be challenging; symptoms of bipolar illness
can be seen in other populations without bipolarity [26]. In
the DSM, fifth edition, increased energy has been added
into the ‘A criterion’ for the diagnosis of the manic features
specifier which is more inclusive than the DSM-IV-TR
diagnosis of manic episode and requires at least three
opposite pole symptoms [27]. It is therefore unclear how
this may affect results of clinical trials that previously
enrolled patients on the basis of DSM-IV-TR criteria.
5 Conclusions
Long-term therapy with asenapine was generally well tol-
erated in pediatric patients aged 10–17 years with BP-1,


























































































Fig. 2 Efficacy during the
open-label extension (OC, full
analysis set). a Least squares
mean change from acute phase
baseline in YMRS total score to
end of treatment by visit;
b Mean (SD) change in CGI-BP
overall score from acute phase
baseline to end of treatment by
visit. The CGI-BP overall score
ranged from 1 (normal, not at all
ill) to 7 (among the most
extremely ill patients).
Decreases from baseline within
a treatment group were
indicative of an improvement.
The YMRS total score could
range from 0 (all symptoms
absent) to 60 (all symptoms
extreme). Decreases from
baseline within a treatment
group are indicative of an
improvement in symptoms. Full
analysis set is all patients B17
years of age who received C1
dose of trial medication and had
both baseline and C1 post-
baseline in-treatment YMRS
total scores in the acute and
extension trial. CGI-BP Clinical
Global Impression scale for use
in bipolar illness, OC observed
case, SD standard deviation,
YMRS Young Mania Rating
Scale
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and 34.8 % experienced clinically significant (C7 %)
weight gain with long-term asenapine therapy. Further
studies are warranted in children and adolescents with BP-
1 to improve our understanding of weight gain and other
metabolic abnormalities associated with long-term ase-
napine treatment, and their relation to the normal changes
that occur in this patient population during growth. The
combination of somnolence, sedation, and hypersomnia
was the most commonly reported TEAE of interest. Som-
nolence and sedation were also among the most common
TEAEs leading to discontinuation and may be treatment-
limiting in a minority of patients.
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